Experimental drug shows promise for rare bone cancers
NCT ID NCT02243605
First seen Mar 13, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a drug called cabozantinib in people whose osteosarcoma or Ewing sarcoma has returned or worsened after standard treatment. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. The main goal is to see if the cancer stays stable or shrinks within 6 months. About 90 participants took part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Strasbourg - Hospital Civil
Strasbourg, 67091, France
-
Center Claudius Regaud
Toulouse, 31052, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Georges-Francois Leclerc
Dijon, 21079, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambert
Lille, 59020, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hopital De La Timone
Marseille, 13385, France
-
Institut Bergonie Cancer Center
Bordeaux, 33076, France
-
Institut Curie Paris
Paris, 75005, France
-
Institut de Cancerologie de l'Ouest-Rene Gauducheau
Saint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.